Switch theme
Sign up to access all valuation multiples
Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.
2010
65
LTM Revenue $11.5M
LTM EBITDA -$39.2M
$52.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sensorion has a last 12-month revenue (LTM) of $11.5M and a last 12-month EBITDA of -$39.2M.
In the most recent fiscal year, Sensorion achieved revenue of n/a and an EBITDA of -$28.5M.
Sensorion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sensorion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $11.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$39.2M | XXX | -$28.5M | XXX | XXX | XXX |
| EBITDA Margin | -343% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$30.9M | XXX | -$31.9M | XXX | XXX | XXX |
| EBIT Margin | -270% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$32.5M | XXX | -$29.2M | XXX | XXX | XXX |
| Net Margin | -284% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sensorion's stock price is EUR 0 (or $0).
Sensorion has current market cap of EUR 121M (or $136M), and EV of EUR 46.3M (or $52.0M).
See Sensorion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52.0M | $136M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sensorion has market cap of $136M and EV of $52.0M.
Sensorion's trades at 9.8x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Sensorion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sensorion has a P/E ratio of -4.2x.
See valuation multiples for Sensorion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $136M | XXX | $136M | XXX | XXX | XXX |
| EV (current) | $52.0M | XXX | $52.0M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | -2.8x | XXX | -2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSensorion's last 12 month revenue growth is 59%
Sensorion's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Sensorion's rule of 40 is -391% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sensorion's rule of X is -195% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sensorion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 59% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -343% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -391% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -195% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sensorion acquired XXX companies to date.
Last acquisition by Sensorion was XXXXXXXX, XXXXX XXXXX XXXXXX . Sensorion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sensorion founded? | Sensorion was founded in 2010. |
| Where is Sensorion headquartered? | Sensorion is headquartered in France. |
| How many employees does Sensorion have? | As of today, Sensorion has 65 employees. |
| Who is the CEO of Sensorion? | Sensorion's CEO is Ms. Nawal Ouzren. |
| Is Sensorion publicy listed? | Yes, Sensorion is a public company listed on PAR. |
| What is the stock symbol of Sensorion? | Sensorion trades under ALSEN ticker. |
| When did Sensorion go public? | Sensorion went public in 2015. |
| Who are competitors of Sensorion? | Similar companies to Sensorion include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sensorion? | Sensorion's current market cap is $136M |
| What is the current revenue of Sensorion? | Sensorion's last 12 months revenue is $11.5M. |
| What is the current revenue growth of Sensorion? | Sensorion revenue growth (NTM/LTM) is 59%. |
| What is the current EV/Revenue multiple of Sensorion? | Current revenue multiple of Sensorion is 4.5x. |
| Is Sensorion profitable? | Yes, Sensorion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sensorion? | Sensorion's last 12 months EBITDA is -$39.2M. |
| What is Sensorion's EBITDA margin? | Sensorion's last 12 months EBITDA margin is -343%. |
| What is the current EV/EBITDA multiple of Sensorion? | Current EBITDA multiple of Sensorion is -1.3x. |
| What is the current FCF of Sensorion? | Sensorion's last 12 months FCF is -$18.7M. |
| What is Sensorion's FCF margin? | Sensorion's last 12 months FCF margin is -163%. |
| What is the current EV/FCF multiple of Sensorion? | Current FCF multiple of Sensorion is -2.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
